7 General discussion and future perspectives 135 112. Gaide Chevronnay HP, Janssens V, Van Der Smissen P, N’Kuli F, Nevo N, Guiot Y, et al. Time course of pathogenic and adaptation mechanisms in cystinotic mouse kidneys. Journal of the American Society of Nephrology : JASN. 2014;25(6):1256-69. 113. Nevo N, Chol M, Bailleux A, Kalatzis V, Morisset L, Devuyst O, et al. Renal phenotype of the cystinosis mouse model is dependent upon genetic background. Nephrol Dial Transplant. 2010;25(4):1059-66. 114. Berlingerio SP, He J, De Groef L, Taeter H, Norton T, Baatsen P, et al. Renal and Extra Renal Manifestations in Adult Zebrafish Model of Cystinosis. Int J Mol Sci. 2021;22(17). 115. Taranta A, Elmonem MA, Bellomo F, De Leo E, Boenzi S, Janssen MJ, et al. Benefits and Toxicity of Disulfiram in Preclinical Models of Nephropathic Cystinosis. Cells. 2021;10(12). 116. Jamalpoor A, van Gelder CA, Yousef Yengej FA, Zaal EA, Berlingerio SP, Veys KR, et al. Cysteamine-bicalutamide combination therapy corrects proximal tubule phenotype in cystinosis. EMBO molecular medicine. 2021;13(7):e13067. 117. Jamalpoor A, Othman A, Levtchenko EN, Masereeuw R, Janssen MJ. Molecular Mechanisms and Treatment Options of Nephropathic Cystinosis. Trends Mol Med. 2021;27(7):673-86. 118. De Leo E, Elmonem MA, Berlingerio SP, Berquez M, Festa BP, Raso R, et al. Cell-Based Phenotypic Drug Screening Identifies Luteolin as Candidate Therapeutic for Nephropathic Cystinosis. Journal of the American Society of Nephrology : JASN. 2020;31(7):1522-37. 119. Wijnhoven TJ, Lensen JF, Wismans RG, Lamrani M, Monnens LA, Wevers RA, et al. In vivo degradation of heparan sulfates in the glomerular basement membrane does not result in proteinuria. J Am Soc Nephrol. 2007;18(3):823-32. 120. Praefcke GJ, McMahon HT. The dynamin superfamily: universal membrane tubulation and fission molecules? Nat Rev Mol Cell Biol. 2004;5(2):133-47. 121. Reiser J, Oh J, Shirato I, Asanuma K, Hug A, Mundel TM, et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem. 2004;279(33):34827-32. 122. Yaddanapudi S, Altintas MM, Kistler AD, Fernandez I, Moller CC, Wei C, et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest. 2011;121(10):3965-80. 123. Kistler AD, Altintas MM, Reiser J. Podocyte GTPases regulate kidney filter dynamics. Kidney Int. 2012;81(11):1053-5. 124. Rashmi P, Sigdel TK, Rychkov D, Damm I, Da Silva AA, Vincenti F, et al. Perturbations in podocyte transcriptome and biological pathways induced by FSGS associated circulating factors. Ann Transl Med. 2023;11(9):315. 125. Ijiri K. Life-cycle experiments of medaka fish aboard the international space station. Adv Space Biol Med. 2003;9:201-16. 126. Drummond IA, Majumdar A, Hentschel H, Elger M, Solnica-Krezel L, Schier AF, et al. Early development of the zebrafish pronephros and analysis of mutations affecting pronephric function. Development. 1998;125(23):4655-67. 127. Ebarasi L, Oddsson A, Hultenby K, Betsholtz C, Tryggvason K. Zebrafish: a model system for the study of vertebrate renal development, function, and pathophysiology. Current opinion in nephrology and hypertension. 2011;20(4):416-24. 128. Modlinska K, Pisula W. The Norway rat, from an obnoxious pest to a laboratory pet. Elife. 2020;9. 129. Comper WD, Vuchkova J, McCarthy KJ. New insights into proteinuria/albuminuria. Front Physiol. 2022;13:991756. 130. Garsen M, Rops AL, Rabelink TJ, Berden JH, van d, V. The role of heparanase and the endothelial glycocalyx in the development of proteinuria. Nephrol Dial Transplant. 2014;29(1):49-55. 131. Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, et al. Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 2012;61(1):208-16.
RkJQdWJsaXNoZXIy MTk4NDMw